metricas
covid
Buscar en
Endocrinología, Diabetes y Nutrición (English ed.)
Toda la web
Inicio Endocrinología, Diabetes y Nutrición (English ed.) Ultrasound calcifications in gallbladder lesions as a sign of suspected neuroend...
Journal Information
Vol. 70. Issue 5.
Pages 367-369 (May 2023)
Vol. 70. Issue 5.
Pages 367-369 (May 2023)
Scientific letter
Full text access
Ultrasound calcifications in gallbladder lesions as a sign of suspected neuroendocrine tumour of the gallbladder
Calcificaciones ecográficas en lesiones vesiculares como criterio de sospecha de tumor neuroendocrino de vesícula biliar
Visits
215
María Cristina Sánchez Chiroboyaa, Blanca Isabel Morón Garcíab, Noemi Brox Torrecillac, Hebert Omar Palomino Donayred, María Miguélez Gonzáleza,
Corresponding author
mariamigo92@gmail.com

Corresponding author.
a Servicio de Endocrinología y Nutrición, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
b Servicio de Oncología Médica, Hospital General Universitario Gregorio Marañón, Madrid, Spain
c Servicio de Endocrinología y Nutrición, Hospital Universitario Ramón y Cajal, Madrid, Spain
d Servicio de Aparato Digestivo, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
This item has received
Article information
Full Text
Bibliography
Download PDF
Statistics
Figures (1)
Full Text

Gallbladder neuroendocrine tumours (GB-NET) are very rare. According to data published in the Surveillance, Epidemiology and End Results (SEER) database, they account for 0.5% of all neuroendocrine tumours (NET) and 2.1% of gallbladder tumours.1 However, a retrospective analysis of SEER data from 1973 to 2016 shows an increase in their incidence of 7% per year in this period.2

These days, GB-NET are usually found by chance in cholecystectomy specimens, and pre-surgical diagnosis is uncommon due to the limitations of tumour markers and imaging techniques such as ultrasound, computed tomography (CT) and magnetic resonance imaging (MRI), which make it difficult to properly diagnose.3 The main diagnostic technique is therefore immunohistochemistry on the cholecystectomy specimen, with the most specific tests being chromogranin A (CgA), synaptophysin and neuron-specific enolase.4

We present a case report of a GB-NET with the finding of calcifications on preoperative ultrasound that led to malignancy being suspected.

This was a 51-year-old woman, former smoker, with a previous history of idiopathic epilepsy. Her family history included her mother, who died of pancreatic cancer, and her father, who died of hepatocellular carcinoma; both having had an alcohol habit. She went to the Accident and Emergency department repeatedly for a year and a half complaining of pain radiating from her right hypochondriac region, nausea and weight loss, with no associated laboratory abnormalities. As a bile duct disorder was suspected, an ultrasound scan was performed, identifying microlithiasis in the gallbladder. In a later magnetic resonance cholangiography scan, only biliary sludge was observed. A second ultrasound revealed a sessile hypoechoic image with an immobile peripheral calcification 13 mm in size, consistent with a polyp (Fig. 1). As malignancy could not be ruled out, a laparoscopic cholecystectomy was performed. The surgical specimen showed a brown polypoid formation in the gallbladder 0.5 × 0.3 cm in size, with free surgical margins, without vascular or lymphatic invasion. Immunohistochemical staining was positive for CK8/18, chromogranin and synaptophysin, and negative for inhibin. It was a G1 well-differentiated GB-NET (Ki-67 = 1%; TNM stage: pT1a). As a staging study, the patient underwent a CT of the chest, abdomen and pelvis, which did not identify distant spread, and somatostatin receptor scintigraphy, without pathological uptake. Successive testing of 5-HIAA and CgA were within the normal ranges. A MEN-1 mutation study was performed, with negative results. The patient is in biochemical and radiological remission, and remains asymptomatic after 6-months follow-up.

Figure 1.

Abdominal ultrasound showing a sessile hypoechoic image in the gallbladder with a peripheral calcification 13 mm in size, consistent with a polyp (indicated by the arrow).

(0.4MB).

GB-NET are more common in females than in males (65.6% versus 34.4%), with a mean age of onset of 65.2 ± 14.3 years. Advanced disease (regional and distant) is found in around 60.3%, meaning they are aggressive tumours.2

The origin of GB-NET is unknown, as there are no neuroectodermal cells in this location,5 but there are several theories as to how they form3:

  • 1)

    Undifferentiated stem cells transform into neoplastic neuroendocrine cells.

  • 2)

    Degeneration of an adenocarcinoma.

  • 3)

    Chronic inflammation caused by cholelithiasis and chronic cholecystitis could lead to gastric or intestinal metaplasia with neuroendocrine cells, ultimately generating a GB-NET.

In most reported cases, carcinoid syndrome is anecdotal, with non-specific symptoms being more common (for example, abdominal pain, nausea, vomiting),3 which, together with low-sensitivity diagnostic tests (tumour markers and imaging tests), makes it difficult to diagnose. Ultrasound only detects alterations in the thickness of the wall, bladder lesions and hypoechoic nodules, while in reported CT and MRI studies, the most common alteration was the greater enhancement of the lesion compared to adenocarcinomas, the main alternative in the differential diagnosis.6 In adenocarcinomas, the most common ultrasound finding is wall thickening, followed by a space-occupying mass. The presence of calcifications is unusual, except where there is coexistence of cholelithiasis or porcelain gallbladder.7 The most cost-effective tool for diagnosis is therefore immunohistochemistry on the surgical specimen. Pathology examination also allows them to be classified, according to the rate of tumour proliferation evaluated by the Ki-67 index, as: low grade/differentiated (G1, Ki-67 index <3%); intermediate grade/moderately differentiated (G2, Ki-67 index ≥3% and ≤20%); or high-grade neoplasms (G3, Ki-67 index >20%), which, according to their differentiation, are subdivided into well-differentiated or poorly differentiated (neuroendocrine carcinomas [NEC]).

Older age, spread, histological grade and early surgery are the main prognostic factors; early diagnosis is therefore essential for establishing the right management plan. The main treatment is surgery, aiming for complete resection (R0).2 Chemotherapy based on regimens of streptozocin, 5-fluorouracil, adriamycin, cisplatin and etoposide is indicated in high-grade/poorly-differentiated GB-NET and NEC in which surgery is not possible, as well as in association with adjuvant radiotherapy of the NEC.8 As with other NET, somatostatin analogues have been used in low-grade GB-NET.9 Radionuclide therapies (Lu-177, Y-99) have also been used, as well as locoregional techniques such as ethanol injection and radiofrequency in liver metastatic lesions. Targeted therapies are not yet available.3

Detection of calcifications in imaging techniques has been reported in gastrointestinal and bronchial NET3; in pancreatic NET, calcifications have also been correlated with a higher histological grade and a more advanced stage, being an independent pre-surgical predictor of lymph node metastasis.10 However, to our knowledge, there are no published cases, either nationally or internationally, of patients with GB-NET who have visible calcifications on imaging studies. In conclusion, we have presented a case in which the finding of calcifications could establish the basis for suspecting malignancy of possible neuroendocrine origin, given the low frequency of calcifications in other histologies. This would enable early diagnosis, along with the determination of markers such as chromogranin, and earlier treatment, thus improving the prognosis.2

Funding

None.

Conflicts of interest

The authors have no conflicts of interest to declare.

References
[1]
J.C. Yao, M. Hassan, A. Phan, C. Dagohoy, C. Leary, J.E. Mares, et al.
One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States.
J Clin Oncol., 26 (2008), pp. 3063-3072
[2]
S. Gogna, D. Samson, M. Gachabayov, A. Rojas, D.M. Felsenreich, D. Koo, et al.
Neuroendocrine neoplasms of the gallbladder: early detection and surgery is key to improved outcome.
Langenbecks Arch Surg., 407 (2022), pp. 197-206
[3]
C. Niu, S. Wang, Q. Guan, X. Ren, B. Ji, Y. Liu.
Neuroendocrine tumors of the gallbladder.
Oncol Lett., 19 (2020), pp. 3381-3388
[4]
J. Soga.
Carcinoids and their variant endocrinomas. An analysis of 11842 reported cases.
J Exp Clin Cancer Res, 22 (2003), pp. 517-530
[5]
T. Adachi, M. Haraguchi, J. Irie, T. Yoshimoto, R. Uehara, S. Ito, et al.
Gallbladder small cell carcinoma: a case report and literature review.
Surg Case Rep., 2 (2016), pp. 71
[6]
F. Yang, Z. Wen.
Computed tomography manifestations and pathological features of neuroendocrine carcinoma in uncommon sites.
Transl Cancer Res., 9 (2020), pp. 6912-6918
[7]
C. Zevallos Maldonado, M.J. Ruiz Lopez, F.M. Gonzalez Valverde, F. Alarcon Soldevilla, F. Pastor Quirante, V. Garcia Medina.
Ultrasound findings associated to gallbladder carcinoma.
Cir Esp., 92 (2014), pp. 348-355
[8]
L. Chiorean, A. Bartos, D. Pelau, D. Iancu, T. Ciuleanu, R. Buiga, et al.
Neuroendocrine tumor of gallbladder with liver and retroperitoneal metastases and a good response to the chemotherapeutical treatment.
J Med Ultrason (2001), 42 (2015), pp. 271-276
[9]
M. Pavel, K. Öberg, M. Falconi, E.P. Krenning, A. Sundin, A. Perren, et al.
Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Ann Oncol., 31 (2020), pp. 844-860
[10]
G.A. Poultsides, L.C. Huang, Y. Chen, B.C. Visser, R.K. Pai, R.B. Jeffrey, et al.
Pancreatic neuroendocrine tumors: radiographic calcifications correlate with grade and metastasis.
Ann Surg Oncol., 19 (2012), pp. 2295-2303
Copyright © 2023. SEEN and SED
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

Quizás le interese:
10.1016/j.endien.2024.01.002
No mostrar más